MA-VELSERA
12.1.2023 19:41:38 CET | Business Wire | Press release
New company Velsera was announced today at the J.P. Morgan Healthcare Conference in San Francisco, California. The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
The promise of precision medicine is held back by barriers across routine health practice and discovery. Existing companies offer partial solutions, but no single company enables the unlocking of insights waiting to be revealed inside data - the status quo is siloed and disconnected. Velsera enables the democratization of omic data across clinical and research applications.
Velsera transforms science, technology, and informatics into an ecosystem of insight, making data actionable through the integration of a rich software platform, deep domain expertise, and knowledge that accelerate the pace and potential of multi-omics. Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
Velsera’s initial formation comes with the acquisition of three global, industry-leading companies in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec. Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights. The integrated business will remain actively engaged with existing customers, enhance current offerings, accelerate new offerings, and bring integrated solutions to market as the leading provider of global omics and insights.
-
Pierian (www.pieriandx.com) - Based in St. Louis, MO, Pierian is a global leader in clinical genomics technology and services supporting a network of laboratories around the globe. Pierian curates the world’s genetic knowledge and offers sophisticated analysis tools to allow for rapid, concise clinical reporting. Its advanced interpretation technology uses adaptive learning algorithms to connect diverse sources of information through machine learning to ensure results are comprehensive and up to date.
-
Seven Bridges (www.sevenbridges.com) - Boston, MA-based Seven Bridges enables researchers to extract meaningful insights from multi-omic, phenotypic and other high throughput data modalities. The Seven Bridges ecosystem consists of a scalable, secure multi-cloud analytic platform, petabytes of connected biomedical data and expert on-demand professional services.
- UgenTec (www.ugentec.com) - Belgian-founded (with U.S. offices) UgenTec brings sample flow intelligence to labs, assay manufacturers and instrument partners to advance modern molecular diagnostics across routine and research applications. UgenTec software and AI solutions deliver workflow automation, testing result interpretation at scale and real-time insights for the digital, connected lab. UgenTec specialties include lab automation, PCR data analysis and clinical-grade software solutions.
Velsera, headquartered in Boston, will be led by CEO Gavin Nichols. Gavin was most recently CEO of the global Medical Imaging and eClincial company Calyx, a spinout from Parexel. He has 30+ years of business experience, with 20 years in the healthcare and pharmaceutical industries. Notably, Gavin was a life science practice partner for several years at Unisys and spent over a decade at Quintiles as a Vice President, covering divisions such as Advanced Analytics, Innovation R&D, Customer Alliances and Partnerships. Nichols has also worked at Capgemini, Bioclinica, Perspectum Diagnostics, and Certara. As the Velsera CEO he will lead a diverse team of industry experts to advance precision medicine and close the value loop between clinical testing, health care and discovery of knowledge and insights for customers that improves global human health.
On leading Velsera, Nichols said: “I am very excited to launch Velsera and look forward to leading the highly accomplished teams from Pierian, Seven Bridges, and UgenTec. Our executive team has knowledge and experience that spans the ecosystem. Collectively we understand the unmet needs of customers and partners, how various stakeholders interact directly and indirectly, and how to uniquely address the unmet needs. As Velsera, we will catalyze the conversion of siloed, global data into insights from clinical and R&D settings to reveal the true promise of precision medicine. We will provide a continuous flow of knowledge among researchers, scientists and clinicians around the world to accelerate the impact of research, expand access to clinical care, and radically improve human health.”
“Summa is driven by a mission to improve the world, through our impact-focused investments in era-defining issues. We believe that the combination of these three leading healthcare and life sciences companies will accelerate innovation and deliver change at remarkable scale, contributing to the Summa thesis and our dedication to the UN Sustainable Development Goals. Velsera’s creation meets UN SDG Goal 3, good health and well-being, by reducing the cost of development of new diagnostics, therapies and drugs, as well as increasing access for underserved populations, and driving global adoption of new bio-computational methods,” comments Hans Cobben, Chair of the Board of Velsera and thematic partner at Summa Equity.
About Velsera
Velsera is the precision engine company. We connect healthcare and life sciences to reveal the true promise of precision medicine - a continuous flow of knowledge among researchers, scientists and clinicians around the world, creating insights that radically improve human health. Today Velsera comprises three global, industry leading organizations in the healthcare and life science industries: Pierian, Seven Bridges, and UgenTec, and growth and expansion should be expected in 2023 and beyond. For more information: velsera.com
About Summa Equity
Summa invests in companies that are solving global challenges and creating positive Environmental, Social, and Governance (ESG) outcomes for society.
Summa’s purpose is to co-create win-win for investors, portfolio companies, and society through aligning its vision and outcomes to the Sustainable Development Goals, ensuring a net-positive impact against ESG challenges, and the potential for long-term, sustainable outperformance.
Investments are focused on industries and companies that have tailwinds from megatrends within three sustainability themes: Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. Across these themes, Summa’s portfolio companies are supporting a world in transition and showing that business can be part of the solution. Summa Equity has c. EUR 4 billion assets under management. For more information: www.summaequity.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005016/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 22:00:00 CEST | Press release
Marks Historic Milestone for U.S. Energy Export Infrastructure under the U.S.-Japan Trade Deal Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom